CN115518133A - Traditional Chinese veterinary medicine composition for treating feline stranguria - Google Patents

Traditional Chinese veterinary medicine composition for treating feline stranguria Download PDF

Info

Publication number
CN115518133A
CN115518133A CN202211326301.4A CN202211326301A CN115518133A CN 115518133 A CN115518133 A CN 115518133A CN 202211326301 A CN202211326301 A CN 202211326301A CN 115518133 A CN115518133 A CN 115518133A
Authority
CN
China
Prior art keywords
traditional chinese
medicine composition
stranguria
low temperature
veterinary medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202211326301.4A
Other languages
Chinese (zh)
Other versions
CN115518133B (en
Inventor
王帅玉
何成蹊
李格宾
范开
董彦君
刘天龙
郝智慧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Agricultural University
Original Assignee
China Agricultural University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Agricultural University filed Critical China Agricultural University
Priority to CN202211326301.4A priority Critical patent/CN115518133B/en
Publication of CN115518133A publication Critical patent/CN115518133A/en
Application granted granted Critical
Publication of CN115518133B publication Critical patent/CN115518133B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
    • A61K36/835—Aquilaria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a traditional Chinese veterinary medicine composition for treating cat stranguria, which is mainly prepared from six raw material medicines of pyrrosia lingua, semen plantaginis, lophatherum gracile, agilawood, radix paeoniae alba and radix glycyrrhizae preparata. The medicine has the effects of clearing heat, excreting dampness, promoting urination, treating stranguria, nourishing liver and yin, promoting qi circulation and relieving pain. The pharmacodynamics research result shows that the medicine has good effects of resisting inflammation, relieving pain and promoting urination.

Description

Traditional Chinese veterinary medicine composition for treating cat stranguria
Technical Field
The invention belongs to the technical field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese veterinary medicine composition for treating cat stranguria and a preparation method thereof.
Background
Feline lower urinary tract syndrome (flute) is a common disease in cats and seriously affects the quality of life and health of cats. Statistically, 3% -5% of cats hospitalized at the pet hospital are due to FLUTD, and about 30% -70% of those suffering from FLUTD will relapse. Flute is a generic term of a series of heterogeneous lower urinary tract diseases with similar clinical symptoms, the main clinical symptoms of cats include dysuria, painful urination, frequent micturition, dripping urine, ectopic micturition and the like, and flute can be mainly divided into Feline Idiopathic Cystitis (FIC), bacterial urinary tract infection, urinary calculi, urinary tract embolus, urinary system anatomical structure abnormality, tumor and the like. Among them, FIC is diagnosed in the most number of cats, accounting for 55% -65% of all flute cases. Several studies have shown that young cats under 10 years of age, particularly 2-7 years of age, are more susceptible to FIC. In addition, factors such as overweight, low activity, living in multi-cat households, and inadequate drinking water may be associated with FIC. The etiology of FIC is complex and ambiguous, and many studies suggest that FIC may be associated with neuroendocrine system abnormalities resulting from various stresses experienced by cats. Recently, there is a literature proposing the replacement of feline idiopathic cystitis by the new term "pandurar syndrome" in order to avoid misunderstandings brought about by the use of specific organ nomenclature, and to pay more attention to systemic multisystem complications associated therewith. The male cat has a narrow urethra, which is easy to cause uroschesis, and if the male cat is not cured in time, uremia and acute renal failure are easy to form, and finally the male cat dies. Mortality rates for cats with flute are 6% -36%. In addition, many cats with recurring FLUTD are euthanized because pet owners are reluctant to repeatedly pay the expensive cost of diagnosis, treatment and hospitalization for sick cats with lower urinary tract symptoms and anuresis, which further increases mortality.
Currently, there is basically no specific drug for treating FIC clinically. In the FIC acute episode, commonly used therapeutic drugs include: antibiotic, anti-inflammatory, spasmolytic and analgesic drugs. However, antibiotics have been shown to be ineffective in treating FIC, the non-steroidal anti-inflammatory drug meloxicam was found to be ineffective in alleviating lower urinary tract symptoms in two clinical trials, and the spasmolytic drugs oxybutynin and propantheline, although capable of alleviating the symptoms of urinary frequency in some cats, randomized controlled studies have shown that more than 70% of FIC cats are also effective when treated with placebo (lactose, wheat flour), indicating that there is not necessarily a causal relationship between medication and symptom improvement. In addition, to reduce the rate of FIC recurrence, or to extend the interval between FIC episodes, the tricyclic antidepressant amitriptyline and the mood-relieving agent pheromone are recommended for long-term use to reduce stress in cats. In addition, mucopolysaccharides are recommended as a replacement for the mucosal layer of the bladder to repair the damaged bladder mucosa in cats with FIC. However, the effectiveness of these drugs has not been validated by clinical trials. Moreover, many of the drugs recommended for use in foreign literature have not been approved for clinical use in pets at home. In the domestic market, some health care products for cats and urinary systems comprise algal sulfated polysaccharides, cranberry extracts, compound vitamins and the like, but the effectiveness of the health care products is not verified by experiments, and most of the health care products are psychological placebo for pet owners. With the development of the pet industry in China, the cat raising population is gradually increased, the base number of pet cats is increased, so that the number of the cat suffering from FLUTD is increased, the suffering of the cat is brought, and the economic burden and the mental stress are brought to a great number of pet owners. Therefore, the research on the new drug for treating FLUTD has certain practical significance.
In middle veterinary medicine, FLUTD belongs to the category of "stranguria" and may be called feline stranguria. The main causes of stranguria in cats include affection of exogenous dampness-heat, improper diet, emotional disorders, congenital deficiency or senile diseases. Referring to the traditional Chinese medicine classification of stranguria, the traditional Chinese veterinary medicine can classify the stranguria of cats into three types, namely heat stranguria (bladder damp-heat type), qi stranguria (liver depression and qi stagnation type) and stranguria caused by overstrain (chronic stranguria type), wherein the former two types are mostly excess syndromes, and the stranguria caused by overstrain is mostly deficiency syndromes. The heat stranguria is caused by the internal generation of damp-heat due to the long-term overeating of the thick taste of the paste beam, the insufficient drinking water and the insufficient movement of the cat, or the invasion of damp-heat evil into the lower jiao. The reason why the existing pet cats are usually confined indoors, the activity range and the enjoyed resources are limited, so that the pet cats cannot fully express the self-natures, and the potential pressure sources in life, such as environmental changes and inharmonious relationship with other family members, and the like, cause the natural sensitive cats to feel anxiety and fear, and cause the cat suffering from liver qi discomfort in the environment for a long time, but the cat is stressed after being stimulated, is easy to catch qi and stagnate liver qi, and cause the stranguria. The stranguria due to overstrain is caused by the decline of the vital qi due to chronic illness or repeated attack of stranguria. Due to the correlation of stressors with FIC, the clinically common FIC-afflicted cats are more prone to stranguria in the middle veterinarian classification. In addition, the feline stranguria syndrome can be classified into bloody stranguria, urolithic stranguria and chylous stranguria according to clinical symptoms, which are marked by bloody urine, fine sand and stones in urine, turbid urine and sticky urine. As described in jin Kui Yao L ü e, the primary symptoms of stranguria include dribbling urine, frequent micturition and odynuria, like urination is like millet, stringy and urgent small abdomen, which leads to umbilicus. Then, if the disease condition further progresses and the blood collaterals are burned, bloody stranguria will appear; stranguria with urinary calculus can occur when damp heat burns urine to become calculus; when damp-heat goes downward and the bladder fails to discharge clear and turbid urine, it may cause stranguria with urinary tract infection such as rice swill or grease. In addition, as described in Yuan Heng treat horse Collection, the "uterus turning" occurs in some stranguria cats with stranguria, i.e. anuresis, if the heat in the bladder is accumulated and the qi stagnation is not good, the flow of the qi is not enough, so that the clear qi is like Yongquan, and the clear qi is not ascending turbid qi and the qi is full and the qi is not enough to be passed through.
The traditional Chinese medicine for treating stranguria has the advantages of safety, small toxic and side effects, obvious short-term and long-term curative effects, low price and the like. However, most of the traditional Chinese medicines are decoction for decoction, and have the defects of inconvenient operation, poor taste, loss of effective components of the medicines, unfavorable popularization and the like. The pyrrosia leaf, the plantain seed and the lophatherum gracile in the invention clear heat, excrete dampness, induce diuresis for treating stranguria, and the agilawood, the white paeony root and the honey-fried licorice root promote qi circulation, relieve pain, nourish liver and nourish yin. The medicines are combined to treat both principal and secondary aspect of disease, strengthen body resistance and eliminate pathogenic factors, can avoid adverse reaction caused by western medicines, obviously improve curative effect and reduce recurrence rate. The invention aims to provide a traditional Chinese veterinary medicine composition for treating cat stranguria, which is convenient to take, can fully retain the active ingredients of the medicine, has stable and controllable quality and can meet the clinical requirement.
Disclosure of Invention
The traditional Chinese veterinary medicine composition with the effects of easing pain, resisting inflammation and promoting urination is prepared by combining the clinical experience of developers under the guidance of the theory of traditional Chinese veterinary medicine and referring to the formula of modern pharmacological research results and pharmacodynamic research.
The invention aims to provide a traditional Chinese veterinary medicine composition for treating cat stranguria, which is convenient to take, can fully retain the active ingredients of the medicine, has stable and controllable quality and can meet the clinical requirement. The invention also aims to provide a preparation method of the medicine.
The invention is realized by the following technical scheme:
the invention provides a traditional Chinese veterinary medicine composition for treating feline stranguria, which is mainly prepared from the following raw material medicines:
pyrrosia leaf 20 parts, plantain seed 20 parts, lophatherum herb 20 parts
20 parts of agilawood, 20 parts of white paeony root, 20 parts of honey-fried licorice root
The preparation method of the traditional Chinese veterinary medicine composition provided by the invention is realized by the following technical scheme:
1) Taking pyrrosia lingua, drying and dehydrating by microwave at low temperature until the water content of the traditional Chinese medicine is below 5%, and pulverizing into powder by using a low-temperature wall breaking machine to obtain traditional Chinese medicine superfine powder with the cell wall breaking rate of above 95% and the powder particle size of below 5 mu m for later use.
2) Drying semen plantaginis with microwave at low temperature to remove water to reduce water content below 5%, and pulverizing with low temperature wall-breaking machine to obtain Chinese medicinal micropowder with cell wall-breaking rate above 95% and particle diameter below 5 μm.
3) Drying herba Lophatheri with microwave at low temperature to remove water to reduce water content below 5%, pulverizing into superfine powder with cell wall breaking rate above 95% and particle diameter below 5 μm.
4) Drying lignum Aquilariae Resinatum with microwave at low temperature to water content below 5%, pulverizing with low temperature wall-breaking machine to obtain Chinese medicinal micropowder with cell wall-breaking rate above 95% and particle diameter below 5 μm.
5) Drying radix Paeoniae alba with microwave at low temperature to remove water to reduce water content below 5%, pulverizing into superfine powder with cell wall breaking rate above 95% and particle diameter below 5 μm.
6) Drying radix Glycyrrhizae Preparata with microwave at low temperature to remove water to reduce water content below 5%, pulverizing into superfine powder with cell wall breaking rate above 95% and particle size below 5 μm.
7) Mixing the superfine powders of the six traditional Chinese medicines obtained in 1), 2), 3), 4), 5) and 6) to obtain a traditional Chinese veterinary medicine composition with analgesic, anti-inflammatory and diuretic effects, adding corresponding medicinal carriers, and making into oral medicine.
The oral medicine can be any one of the oral dosage forms in pharmaceutics.
The oral medicine includes but is not limited to powder and capsule.
The oral powder can be prepared by the following method: taking 120 parts of the prepared traditional Chinese veterinary medicine composition, further grinding, stirring and uniformly mixing by using a small electric grinding machine, averagely dividing into 10 bags, wherein each bag contains 12 parts of the traditional Chinese veterinary medicine composition, and carrying out hot-pressing plastic packaging to obtain the traditional Chinese veterinary medicine composition.
The oral capsule can be prepared by the following method: taking 300 parts of the prepared traditional Chinese veterinary medicine composition, further grinding, stirring and uniformly mixing by using a small electric grinder, evenly packaging the traditional Chinese veterinary medicine composition into 100 capsules of No. 0 by using a No. 0 capsule plate with 100 holes, wherein each capsule contains 3 parts of the traditional Chinese veterinary medicine composition, and covering a capsule cap to obtain the traditional Chinese veterinary medicine composition.
The medicine has the effects of clearing heat, excreting dampness, inducing diuresis, treating stranguria, nourishing liver and yin, promoting qi circulation and relieving pain, and has the effects of resisting inflammation, relieving pain and inducing diuresis. The medicine of the invention is convenient to take, can fully retain the effective components of the medicine, has stable and controllable quality, no adverse reaction and obvious curative effect.
The present invention is further illustrated by the following specific examples and pharmacodynamic test results.
Detailed Description
The present invention is further described with reference to the following examples, which are not intended to be limiting, but rather are intended to be exemplary of the prior art, which is known in the art, and therefore all equivalent alterations of this invention are intended to be embraced therein.
Example 1:
prescription:
2g of pyrrosia leaf, 2g of plantain seed, 2g of lophatherum gracile and 2g of lophatherum gracile
2g of agilawood, 2g of white peony root, 2g of honey-fried licorice root and 2g of honey-fried licorice root
Making into 10 bags
The preparation method comprises the following steps:
taking pyrrosia lingua, semen plantaginis, lophatherum gracile, agilawood, radix paeoniae alba and radix glycyrrhizae preparata according to a prescription, respectively drying and dehydrating at low temperature by microwave to ensure that the water content of the traditional Chinese medicinal materials is below 5%, respectively pulverizing by using a low-temperature wall breaking machine to prepare traditional Chinese medicine superfine powder with the cell wall breaking rate of above 95% and the powder particle size of below 5 mu m, uniformly mixing to prepare the traditional Chinese veterinary medicine composition, further grinding, stirring and uniformly mixing by using a small electric pulverizer, averagely dividing into 10 bags, wherein each bag contains 1.2g of the traditional Chinese veterinary medicine composition, and carrying out hot-press plastic packaging to obtain the traditional Chinese veterinary medicine composition.
Example 2:
prescription:
5g of pyrrosia leaf, plantain seed and 5g of lophatherum gracile
Agilawood 5g white peony root 5g honey-fried licorice root 5g
Making into 100 capsules
The preparation method comprises the following steps:
taking pyrrosia lingua, plantain seed, lophatherum gracile, agilawood, white paeony root and honey-fried licorice root according to a prescription, respectively drying and dehydrating at low temperature by microwave to ensure that the water content of the traditional Chinese medicinal materials is below 5 percent, respectively pulverizing the traditional Chinese medicinal materials by using a low-temperature wall breaking machine to prepare traditional Chinese medicine superfine powder with the cell wall breaking rate of above 95 percent and the particle size of the powder of below 5 mu m, uniformly mixing the traditional Chinese medicine superfine powder to prepare the traditional Chinese veterinary medicine composition, further grinding the traditional Chinese veterinary medicine superfine powder by using a small-sized electric pulverizer, stirring and uniformly mixing the powder, using a No. 0 capsule plate with 100 holes, uniformly packaging the traditional Chinese veterinary medicine composition into No. 0 capsules with 100 granules, wherein each capsule contains 0.3g of the traditional Chinese veterinary medicine composition, and covering a capsule cap to obtain the traditional Chinese veterinary medicine composition.
Example 3:
prescription:
1g of pyrrosia leaf, plantain seed and 1g of lophatherum gracile
Agilawood 1g white peony root 1g honey-fried licorice root 1g
Making into suspension of 0.2g/mL
The preparation method comprises the following steps:
taking pyrrosia lingua, semen plantaginis, lophatherum gracile, agilawood, radix paeoniae alba and radix glycyrrhizae preparata according to a prescription, respectively drying and dehydrating at low temperature by microwave to ensure that the water content of the traditional Chinese medicinal materials is below 5%, respectively pulverizing the traditional Chinese medicinal materials into powder by using a low-temperature wall breaking machine to prepare traditional Chinese medicine superfine powder with the cell wall breaking rate of above 95% and the powder particle size of below 5 mu m, uniformly mixing to prepare the traditional Chinese veterinary medicine composition, and adding 30mL of distilled water to prepare a suspension of 0.2g/mL.
Example 4: pharmacodynamic test
The invention provides a traditional Chinese veterinary medicine composition with anti-inflammatory, analgesic and diuretic effects, and in order to prove the treatment effect, the inventor performs pharmacodynamic tests by using the suspension prepared by the method provided in example 3, and the research results are as follows:
1. anti-inflammatory action
1) Test materials
The suspension of the veterinary herbal composition prepared in example 3 of the present invention was at a concentration of 0.2g/mL.
2) Test method
18 healthy SPF-level Kunming mice with the age of 4 weeks and the weight of 25 +/-2 g are randomly divided into 3 groups, 6 mice in each group and half of males and females. The test results are respectively a negative control (distilled water) group, a positive control (2.5 mg/mL indometacin) group and an experimental group (0.2 g/mL traditional Chinese veterinary medicine composition). After adaptive feeding for 3 days, the medicine is administrated by gavage once a day, 0.2mL is taken every time, and the medicine is continuously administrated for 3 days. After 30min of the last administration, 50 μ L of xylene was evenly spread on the front and back sides of the auricle of the right ear of each mouse, and the left ear was used as a control. After 30min of inflammation, dislocation of cervical vertebrae of the mouse is killed, two ears are cut along the auricle base line, round ear pieces are punched at the same positions of the two ears by a puncher with the diameter of 6mm, and the round ear pieces are accurately weighed on a ten-thousandth precision electronic balance. The degree of swelling is represented by the difference between the weights of the left and right ear pieces, and the intensity of the anti-inflammatory action is represented by the inhibition ratio. Degree of swelling (mg) = inflamed-side ear weight (mg) — non-inflamed-side ear weight (mg), inhibition (%) = (average degree of swelling of negative control group-average degree of swelling of administration group)/average degree of swelling of negative control group × 100%. For experimental data
Figure BDA0003907768310000063
The experimental results are shown to be processed using SPSS 26.0 statistical software. The comparison among groups is carried out by adopting one-way anova, wherein the LSD method is used for the uniform anova and the Dunnet method is used for the anovat's T 3 The method tests that P <0.05 indicates that significant difference exists. Specific results are shown in table 1.
TABLE 1 Effect of different drug preparations on swelling of mouse auricles by Paralyne: (
Figure BDA0003907768310000061
n＝6)
Figure BDA0003907768310000062
Note: * Represents that the P of each administration group is less than 0.05 compared with the negative control group. Δ represents P >0.05 in the experimental group compared to the positive control group.
As shown in table 1, the swelling degree of the pinna in the positive control group and the experimental group is obviously smaller than that in the negative control group, and the difference is significant (P < 0.05). The swelling degree of the auricle of the experimental group is not significantly different from that of the positive control group (P > 0.05).
The results show that the positive control group and the experimental group have obvious inhibition effect on mouse ear swelling caused by xylene, and the effect of the veterinary drug composition in the experimental group is equivalent to that of the positive control drug, which shows that the traditional Chinese veterinary drug composition has obvious anti-inflammatory effect.
2. Analgesic effect
2.1 Effect of different drug preparations on the pain threshold of the mouse thermal stimulation
1) Test materials
The suspension of the veterinary herbal composition prepared in example 3 of the present invention was at a concentration of 0.2g/mL.
2) Test method
A plurality of healthy female SPF-level Kunming mice with the age of 4 weeks and the body weight of 25 +/-2 g are taken and adaptively bred for 3 days. The method comprises the steps of measuring a basic pain threshold value of a mouse on a hot plate at 55.0 +/-0.5 ℃ by using an intelligent hot plate instrument, namely the time required by the mouse to lick feet is repeated for 3 times, the interval of each time is 5min, calculating the average number, selecting 18 mice with the basic pain threshold value of 5-30 s and no jump reaction, and randomly dividing the mice into 3 groups of 6 mice each. Respectively as a negative control group (distilled water) and a positive control group (2.5 mg/mL indometacin)) Experimental group (0.2 g/mL veterinary composition). The medicine is administered by gavage once a day, 0.2mL each time, and is administered continuously for 3 days. Respectively measuring pain threshold of each mouse on a hot plate at 55.0 + -0.5 deg.C by using an intelligent hot plate instrument after last administration for 15min, 30min, 60min and 90min, stopping the experiment and taking out the mouse if the pain threshold reaches 60s so as to avoid scalding the palm of the mouse, wherein the pain threshold of the mouse is calculated by 60 s. The intensity of analgesic effect is expressed as the rate of increase of pain threshold. Pain threshold increase rate (%) = (pain threshold after administration-basal pain threshold)/basal pain threshold × 100%. For experimental data
Figure BDA0003907768310000073
The experimental results are shown to be processed using SPSS 26.0 statistical software. One-way anova was used for comparisons between groups, with LSD for homogeneous anova and Dunnett's T for non-homogeneous anova 3 The method tests that P <0.05 indicates that the significant difference exists. Specific results are shown in Table 2.
Table 2 influence of different drug preparations on the pain threshold of the mice by thermal stimulation: (
Figure BDA0003907768310000071
n＝6)
Figure BDA0003907768310000072
Figure BDA0003907768310000081
Note: * Represents that the P of each administration group is less than 0.05 compared with the negative control group. And a circle represents that P is less than 0.05 in the experimental group compared with the positive control group, and a triangle represents that P is more than 0.05 in the experimental group compared with the positive control group.
As can be seen from Table 2, the pain threshold increase rates of the positive control group and the experimental group after administration for 15min, 30min, 60min and 90min are all significantly greater than those of the negative control group, and the difference is significant (P is less than 0.05). The pain threshold improvement rate of the experimental group 15min and 30min after administration is smaller than that of the positive control group, and the difference is significant (P is less than 0.05). The pain threshold increase rate of the experimental group 60min after administration is greater than that of the positive control group, and the difference is significant (P < 0.05). The pain threshold increase rate of the test group 90min after administration was not significantly different from that of the positive control group (P > 0.05).
The results show that the pain threshold of the thermal stimulation of the mouse can be obviously improved in different time periods after the administration of the positive control group and the experimental group, the positive control drug has relatively more obvious effects 15min and 30min after the administration compared with the veterinary drug composition in the experimental group, but the effect of the veterinary drug composition in the experimental group is more obvious than the effect of the positive control drug 60min after the administration compared with the positive control drug, and the effects of the veterinary drug composition in the experimental group and the positive control drug 90min after the administration are equivalent, which indicates that the traditional Chinese veterinary drug composition has an obvious analgesic effect and a better long-acting analgesic effect.
2.2 Effect of different drug preparations on the acetic acid writhing response in mice
1) Test materials
The suspension of the veterinary herbal composition prepared in example 3 of the present invention was at a concentration of 0.2g/mL.
2) Test method
18 healthy SPF-level Kunming mice with age of 4 weeks and weight of 25 +/-2 g are randomly divided into 3 groups of 6 mice each with half of male and female. The test results are respectively a negative control group (distilled water), a positive control group (2.5 mg/mL indometacin) and an experimental group (0.2 g/mL traditional Chinese veterinary medicine composition). After adaptive feeding for 3 days, the medicine is administrated by gavage once a day, 0.2mL is taken every time, and the medicine is continuously administrated for 3 days. 30min after the last administration, 0.6% glacial acetic acid 0.1ml/10g is injected into the abdominal cavity of each mouse, and the time (latency period) for each mouse to wriggle for the first time and the wriggling frequency of the mouse within 20min are recorded. The analgesic effect intensity is expressed by the elongation and analgesic rate. Elongation (%) = [ (drug administration latency-negative control latency)/negative control latency × 100%. Analgesic rate (%) = (average number of twists in negative control group-average number of twists in administration group)/average number of twists in negative control group × 100%. For experimental data
Figure BDA0003907768310000082
The experimental results are shown to be processed using SPSS 26.0 statistical software. Comparison between groups adopts sheetAnalysis of variance of factors, with LSD for the uniform variance and Dunnett's T for the anomalva 3 The method tests that P <0.05 indicates that significant difference exists. The specific results are shown in Table 3.
Table 3 effect of different drug preparations on the acetic writhing response in mice: (
Figure BDA0003907768310000091
n＝6)
Figure BDA0003907768310000092
Note: * Represents that the P of each administration group is less than 0.05 compared with the negative control group. And a circle represents that P is less than 0.05 in the experimental group compared with the positive control group, and a triangle represents that P is more than 0.05 in the experimental group compared with the positive control group.
As shown in Table 3, compared with the negative control group, the number of writhing and the incubation period of each administration group are significantly different (P is less than 0.05), which indicates that the modeling of the experiment is successful. The incubation period of the experimental group was not significantly different from the positive control group (P > 0.05). The number of writhing times of the experimental group is different from that of the positive control group with significance (P < 0.05).
The result shows that the incubation period of the acetate writhing of the mouse can be remarkably prolonged by both the positive control group and the experimental group, the times of the acetate writhing reaction of the mouse are remarkably reduced, and although the effect of the veterinary drug composition in the experimental group on reducing the times of the acetate writhing of the mouse is relatively more remarkable compared with the effect of the veterinary drug composition in the experimental group, the effect of the veterinary drug composition in the experimental group on prolonging the incubation period of the mouse is equivalent to that of the positive control drug, so that the traditional Chinese veterinary drug composition has an obvious analgesic effect.
3. Diuretic effect
1) Test materials
The suspension of the veterinary herbal composition prepared in example 3 of the present invention was at a concentration of 0.2g/mL.
2) Test method
Taking a plurality of healthy SPF-level Kunming mice with age of 4 weeks and weight of 25 +/-2 g, placing the mice in a mouse metabolism cage for adaptive breeding for 3 days, and allowing the mice to drink water, diet and urine volume freelyAnd (5) screening after stabilization. Before screening, the mice are fasted for 12 hours without water prohibition, before operation, the lower abdomen of the mice is lightly pressed, residual urine is drained, distilled water is given according to the gavage of 0.2mL/10g, the urine is collected for 2 hours, 18 mice with the urine amount of more than 40 percent of the given amount are selected to be brought into the formal experiment, the mice are divided into 3 groups at random, each group comprises 6 mice, and the male and female are half of each other. The test group respectively comprises a negative control group (distilled water), a positive control group (2.5 mg/mL hydrochlorothiazide) and an experimental group (0.2 g/mL of the traditional Chinese veterinary medicine composition). The medicine is administered by gavage once a day, 0.2mL each time, and is administered continuously for 3 days. The mice are fasted for 12 hours before the last administration without water prohibition, the animals are lightly pressed to lower the abdomen before the experiment, the residual urine is drained, and the physiological saline is injected into the abdominal cavity of each mouse for 0.2mL/10g, and the mice are immediately administered by intragastric administration. Urine volume of each mouse was measured and recorded at 1h, 2h, 3h, 4h, 5h, 6h, and 24h after the last administration, and urine volume per kg body weight was calculated. For experimental data
Figure BDA0003907768310000101
The experimental results are shown to be processed using SPSS 26.0 statistical software. One-way anova was used for comparisons between groups, with LSD for homogeneous anova and Dunnett's T for non-homogeneous anova 3 The method tests that P <0.05 indicates that significant difference exists. The specific results are shown in Table 4.
TABLE 4 diuretic Effect of different drug preparations on mice: (
Figure BDA0003907768310000102
n＝6)
Figure BDA0003907768310000103
Note: * Represents that the P of each administration group is less than 0.05 compared with the negative control group. And a circle represents that P is less than 0.05 in the experimental group compared with the positive control group, and a triangle represents that P is more than 0.05 in the experimental group compared with the positive control group.
As can be seen from Table 4, the urine volume in different time periods after the administration of the positive control group and the experimental group is obviously larger than that in the negative control group, which indicates that the modeling of the experiment is successful. Except for 2h after administration, the difference of urine volume between the experimental group and the positive control group is significant (P < 0.05), and the difference between the experimental group and the positive control group is not significant in other time periods (P > 0.05).
The result shows that the positive control group and the experimental group can both use the urine volume of the mice in different time periods after administration, and the effect of the veterinary drug composition in the experimental group is equivalent to that of the positive control drug, which indicates that the traditional Chinese veterinary drug composition has an obvious diuretic effect.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.

Claims (5)

1. The traditional Chinese veterinary medicine composition for treating the cat stranguria is characterized by comprising the following components:
Figure FDA0003907768300000011
the preparation method comprises the following steps:
1) Taking pyrrosia lingua, drying and dehydrating by microwave at low temperature until the water content of the traditional Chinese medicinal materials is below 5%, and pulverizing into powder by using a low-temperature wall breaking machine to obtain traditional Chinese medicine superfine powder with the cell wall breaking rate of above 95% and the powder particle size of below 5 mu m for later use;
2) Drying semen plantaginis with microwave at low temperature to remove water to reduce water content below 5%, and pulverizing with low temperature wall-breaking machine to obtain Chinese medicinal micropowder with cell wall-breaking rate above 95% and particle diameter below 5 μm;
3) Drying folium Bambusae with microwave at low temperature to remove water to water content below 5%, pulverizing with low temperature wall-breaking machine to obtain Chinese medicinal micropowder with cell wall-breaking rate above 95% and particle diameter below 5 μm;
4) Drying lignum Aquilariae Resinatum with microwave at low temperature to water content below 5%, pulverizing with low temperature wall-breaking machine to obtain Chinese medicinal superfine powder with cell wall-breaking rate above 95% and particle diameter below 5 μm;
5) Drying radix Paeoniae alba with microwave at low temperature to remove water to reduce water content below 5%, pulverizing with low temperature wall-breaking machine to obtain Chinese medicinal micropowder with cell wall-breaking rate above 95% and particle diameter below 5 μm;
6) Drying radix Glycyrrhizae Preparata with microwave at low temperature to remove water to reduce water content below 5%, pulverizing into superfine powder with cell wall breaking rate above 95% and particle diameter below 5 μm;
7) Mixing the superfine powders of the six Chinese medicinal materials obtained in 1), 2), 3), 4), 5) and 6) to prepare the oral medicament.
2. The veterinary Chinese medicine composition for treating feline stranguria according to claim 1, wherein said oral medicine can be any one of the pharmaceutical oral dosage forms.
3. The veterinary drug composition for treating feline stranguria according to claim 1, wherein the oral drugs include but are not limited to powder and capsules.
4. The veterinary herbal composition for treating feline stranguria according to claim 1, wherein said oral powder is prepared by the following steps: taking 120 parts of the prepared traditional Chinese veterinary medicine composition, further grinding, stirring and uniformly mixing by using a small electric grinding machine, averagely dividing into 10 bags, wherein each bag contains 12 parts of the traditional Chinese veterinary medicine composition, and carrying out hot-pressing plastic packaging to obtain the traditional Chinese veterinary medicine composition.
5. The veterinary Chinese medicine composition for treating feline stranguria according to claim 1, wherein the oral capsule is prepared by the following steps: taking 300 parts of the prepared traditional Chinese veterinary medicine composition, further grinding, stirring and uniformly mixing by using a small electric grinder, evenly packaging the traditional Chinese veterinary medicine composition into 100 capsules of No. 0 by using a No. 0 capsule plate with 100 holes, wherein each capsule contains 3 parts of the traditional Chinese veterinary medicine composition, and covering a capsule cap to obtain the traditional Chinese veterinary medicine composition.
CN202211326301.4A 2022-10-25 2022-10-25 Traditional Chinese veterinary medicine composition for treating cat stranguria Active CN115518133B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211326301.4A CN115518133B (en) 2022-10-25 2022-10-25 Traditional Chinese veterinary medicine composition for treating cat stranguria

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211326301.4A CN115518133B (en) 2022-10-25 2022-10-25 Traditional Chinese veterinary medicine composition for treating cat stranguria

Publications (2)

Publication Number Publication Date
CN115518133A true CN115518133A (en) 2022-12-27
CN115518133B CN115518133B (en) 2023-07-25

Family

ID=84703665

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211326301.4A Active CN115518133B (en) 2022-10-25 2022-10-25 Traditional Chinese veterinary medicine composition for treating cat stranguria

Country Status (1)

Country Link
CN (1) CN115518133B (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1679692A (en) * 2005-02-03 2005-10-12 李浪辉 Medicine for gonorrhea and its preparation
CN102949607A (en) * 2011-08-31 2013-03-06 施瑞客（天津）生物技术有限公司 Traditional Chinese medicine composition for treating haematuria of cats
CN103860695A (en) * 2014-02-27 2014-06-18 广西壮族自治区中医药研究院 Traditional Chinese medicine (TCM) composition for treating syndrome of dampness-heat in lower jiao caused by stranguria, and preparation method

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1679692A (en) * 2005-02-03 2005-10-12 李浪辉 Medicine for gonorrhea and its preparation
CN102949607A (en) * 2011-08-31 2013-03-06 施瑞客（天津）生物技术有限公司 Traditional Chinese medicine composition for treating haematuria of cats
CN103860695A (en) * 2014-02-27 2014-06-18 广西壮族自治区中医药研究院 Traditional Chinese medicine (TCM) composition for treating syndrome of dampness-heat in lower jiao caused by stranguria, and preparation method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
林才生;: "石韦散化裁治疗石淋体会", 中医药学刊, no. 02, pages 1 - 3 *

Also Published As

Publication number Publication date
CN115518133B (en) 2023-07-25

Similar Documents

Publication Publication Date Title
CN100428950C (en) Medicine for preventing and treating chicken kidney swelling disease
CN102579597B (en) Chinese herbal compound prescription for preventing and curing mammitis of mammalian livestock and method for preparing same
CN103432312A (en) Traditional Chinese medicine composition used for treating pig scabies
CN1325107C (en) Composition for treating bee disease and medicinal fodder
CN102247570B (en) Traditional Chinese medicine composition for treating cow ketosis
CN115518133B (en) Traditional Chinese veterinary medicine composition for treating cat stranguria
CN105434915A (en) Pharmaceutical composition for treating urolithiasis for dogs and cats and preparation method of pharmaceutical composition
CN101390883A (en) Dried wood-louse extract, preparation method and use thereof in preparing analgesic
CN114515307A (en) A veterinary drug composition or animal food additive for preventing and/or treating kidney diseases
CN101049345A (en) A preparation for treating disease of oral cavity and gorge, and preparation method
CN1824204A (en) Medicinal composition for treating acute urarthritis and its preparation method
CN101966278B (en) Traditional Chinese medicine for treating urinary tract infection and preparation method thereof
CN110882345A (en) Traditional Chinese medicine composition for preventing and treating postpartum abdominal pain of dairy cows and preparation method thereof
CN115607632A (en) A veterinary Chinese medicinal composition with antiinflammatory, analgesic and diuretic effects
CN101524447A (en) Pharmaceutical composition for treating constipation and preparation process thereof
CN1251751C (en) Chinese traditional medicine for treating chronic liver disease and anti hepatic fibrosis
CN101209315A (en) Chinese medicinal injection with antimicrobial and anti-inflammation, milk-smoothing and mass-dissipating efficacy
CN115845003B (en) Application of traditional Chinese medicine composition in preparation of medicine for treating arthritis
CN1069054C (en) Medicine for external use for curing chronic prostatitis
CN102335362A (en) Traditional Chinese medicine for treating insulin resistance of type 2 diabetes
CN103405745A (en) Traditional Chinese medicine composition for treating canine gastroenteritis
CN1301728C (en) Chinese medicine compound preparation for treating osteoarthropathy and its preparation method
CN1186052C (en) Medicine for treatment of pelvic inflammation, its preparation and preparing method
CN101618118B (en) Application of Chinese medicinal composition in preparing medicament for treating cystitis
CN115317457B (en) Stomach-invigorating and ruminant-promoting traditional Chinese medicine tablet for cattle and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant